celecoxib has been researched along with Injuries, Tendon in 6 studies
Excerpt | Relevance | Reference |
---|---|---|
" However, clinical data suggest that chronic use of celecoxib, may impair normal skeletal function leading to decreased bone mineral density in older male patients." | 2.44 | Celecoxib, NSAIDs and the skeleton. ( Lysz, T; O'Connor, JP, 2008) |
"Lactoferrin has a great potential for the tendon regeneration." | 1.91 | Screening for autophagy/hypoxia/ferroptosis/pyroptosis-related genes of tendon injury and repair in a rat model after celecoxib and lactoferrin treatment. ( Min, N; Shi, L; Wang, F; Wang, L; Wen, L; Xue, Q; Zhang, Y, 2023) |
"Indomethacin (3 mg/kg) was then compared to celecoxib (4." | 1.32 | Indomethacin and celecoxib improve tendon healing in rats. ( Aspenberg, P; Bylander, B; Forslund, C, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Zhang, Y | 1 |
Shi, L | 1 |
Wang, F | 1 |
Wang, L | 1 |
Min, N | 1 |
Wen, L | 1 |
Xue, Q | 1 |
Jiang, S | 1 |
Yan, H | 1 |
Fan, D | 1 |
Song, J | 1 |
Fan, C | 1 |
Lu, Y | 1 |
Li, Y | 1 |
Li, FL | 1 |
Li, X | 1 |
Zhuo, HW | 1 |
Jiang, CY | 1 |
O'Connor, JP | 1 |
Lysz, T | 1 |
Forslund, C | 1 |
Bylander, B | 1 |
Aspenberg, P | 1 |
Cohen, DB | 1 |
Kawamura, S | 1 |
Ehteshami, JR | 1 |
Rodeo, SA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder[NCT02588027] | 100 participants (Anticipated) | Interventional | 2015-10-31 | Active, not recruiting | |||
Rotator Cuff Tendinopathy: A Randomized and Blinded Comparison of Superficial and Deep Injection Methods[NCT01402011] | 77 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Participants were asked about pain at rest, at work, doing sports. The maximum pain reported on a scale ranging from 0 (no pain at all) to 10 (extreme pain) was recorded for each participant. Maximum of pain scores rest, work, sport recorded. Calculated as pain at baseline - pain at 9 months. (NCT01402011)
Timeframe: baseline and 9 months
Intervention | units on a scale (Mean) |
---|---|
25% Dextrose in Ligaments and Tendons | 2.9 |
.1% Lidocaine in Ligaments and Tendons | 1.8 |
.1% Lidocaine Subcutaneous | 1.3 |
Subject marks his pain level at rest, at work, doing sports on a 10 cm scale. Maximum of pain scores rest, work, sport recorded. Calculated as pain at baseline - pain at 3 months. VAS scale is from 0 = no pain to 10 = maximum pain (NCT01402011)
Timeframe: baseline and three months
Intervention | units on a scale (Mean) |
---|---|
25% Dextrose in Ligaments and Tendons | 3.0 |
.1% Lidocaine in Ligaments and Tendons | 2.7 |
.1% Lidocaine Subcutaneous | 2.7 |
Phone call asking how satisfied were they with their treatment 10 = extremely satisfied, 0 = extremely dissatisfied ) (NCT01402011)
Timeframe: Nine months after first injection treatment appointment
Intervention | units on a scale (Mean) |
---|---|
25% Dextrose in Ligaments and Tendons | 6.7 |
.1% Lidocaine in Ligaments and Tendons | 4.7 |
.1% Lidocaine Subcutaneous | 3.9 |
Subject marks his pain level at rest, at work, doing sports on a 10 cm scale. The maximum pain level among the 3 different activities was recorded. (NCT01402011)
Timeframe: 20 minutes before first injection on first day of patient visit
Intervention | units on a scale (Mean) |
---|---|
25% Dextrose in Shoulder Entheses | 7.3 |
.1% Lidocaine in Shoulder Entheses | 6.9 |
.1% Lidocaine Subcu. Above Shouldr Enth. | 6.9 |
http://www.dash.iwh.on.ca/assets/images/pdfs/DASH_quest06.pdf 30 questions assessing ability to use shoulder in everyday activities, each question scored 1 to 5, where one is normal, no problem and five is unable to perform. No data was collected at 9 months. The score ranges from 30 to 150. Higher scores represent worse outcomes. (NCT01402011)
Timeframe: 20 minutes before the first injection and at 3 months
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | 3 months | |
.1% Lidocaine in Ligaments and Tendons | 71.3 | 54.7 |
.1% Lidocaine Subcutaneous | 69.6 | 61 |
25% Dextrose in Ligaments and Tendons | 72.4 | 61.3 |
From Steven W. Brose, DO, Michael L. Boninger, MD, Bradley Fullerton, MD, Thane McCann, MD, From: Jennifer L. Collinger, BSE, Bradley G. Impink, BSE, Trevor A. Dyson-Hudson, MD Shoulder ultrasound abnormalities, physical examination findings, and pain in manual wheelchair users with spinal cord injury. Arch Phys Med Rehabil 2008 Nov; 89:2086-93, appendix 1 12 parameters of shoulder examination: Biceps tendon/bicipital groove tenderness, Supraspinatus tendon/greater tuberosity tenderness Acromioclavicular joint tenderness Resisted external rotation. Resisted internal rotation. Supraspinatus test. Painful Arc Test. Neer impingement sign. Hawkins-Kennedy impingement sign. O'Brien Active Compression Test for AC Joint Pathology O'Brien Active Compression Test for Labral Pathology impingement sign. each test scored 0 = no pain, 1 = tenderness, 2 = pain. All 12 scores added. Range 0-24. Higher scores = more pathology (NCT01402011)
Timeframe: 20 minutes before first injection on first day of patient visit and at 3 months
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | 3 months | |
.1% Lidocaine in Ligaments and Tendons | 13.1 | 10.7 |
.1% Lidocaine Subcutaneous | 13 | 12.9 |
25% Dextrose in Ligaments and Tendons | 13.2 | 11.4 |
"From Brose et al. shoulder ultrasound abnormalities, physical examination findings, and pain in manual wheelchair users with spinal cord injury Arch Phys Med Rehabil 2008 Nov, 89: 2086-93 appendix 2. rates biceps tendinopathy (0-6), supraspinatus tendinopathy (0-5), greater tuberosity the cortical surface (0-3), dynamics supraspinatus impingement (0-3), dynamic subscapularis/ biceps/ coracoid impingement (0-3). The total score ranged from 0 to 20 with higher scores indicating a worse outcome. The change was calculated by taking the final score - the baseline score." (NCT01402011)
Timeframe: 20 minutes before first injection on first day of patient visit and at on average 9.4 months
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | change at 9.4 +/- 2.2 months | |
.1% Lidocaine in Ligaments and Tendons | 4.3 | -0.6 |
.1% Lidocaine Subcutaneous | 4.3 | -0.6 |
25% Dextrose in Ligaments and Tendons | 4.0 | -0.3 |
1 review available for celecoxib and Injuries, Tendon
Article | Year |
---|---|
Celecoxib, NSAIDs and the skeleton.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Bone and Bones; Bone Regeneration; Cele | 2008 |
1 trial available for celecoxib and Injuries, Tendon
Article | Year |
---|---|
Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Indomethacin; Male; New York City; Pyra | 2006 |
Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Indomethacin; Male; New York City; Pyra | 2006 |
Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Indomethacin; Male; New York City; Pyra | 2006 |
Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Indomethacin; Male; New York City; Pyra | 2006 |
4 other studies available for celecoxib and Injuries, Tendon
Article | Year |
---|---|
Screening for autophagy/hypoxia/ferroptosis/pyroptosis-related genes of tendon injury and repair in a rat model after celecoxib and lactoferrin treatment.
Topics: Animals; Celecoxib; Ferroptosis; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; L | 2023 |
Multi-layer electrospun membrane mimicking tendon sheath for prevention of tendon adhesions.
Topics: Animals; Biomechanical Phenomena; Biomimetic Materials; Celecoxib; Collagen; Hyaluronic Acid; Membra | 2015 |
Do Different Cyclooxygenase Inhibitors Impair Rotator Cuff Healing in a Rabbit Model?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Celecoxib; Cyclooxygenase | 2015 |
Indomethacin and celecoxib improve tendon healing in rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Sectional S | 2003 |